CMND Berita Valas
Clearmind Medicine Says It Completed Type A Meeting With FDA; Stock Up 38%
Biotech company Clearmind Medicine, Inc. (CMND) announced Wednesday it has completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of Alcohol Use Disorder treatment (AUD) using its novel psychedelic- based therapy.
RTTNews
|
994 hari yang lalu
